| COVID-19 | has | incubation period (count: 4) | |
|---|---|
| Firstly, COVID-19 has a relatively long incubation period, which causes a time delay between real dynamic and the dailyobserved case numbers.
-- Modeling the Epidemic Dynamics and Control of COVID-19 Outbreak in China. medrxiv. 2020-02-29. | |
| COVID-19 is spread by human-to-human transmission through droplet, feco-oral, and direct contact and has an incubation period of 2-14 days [6] .
-- Novel Coronavirus (COVID-19) Knowledge and Perceptions: A Survey of Healthcare Workers. medrxiv. 2020-03-13. | |
| COVID-19 has a mean incubation period of 5.2 days (95% confidence interval, 4.1-7.0).
-- Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP). J Chin Med Assoc. 2020. | |
| COVID-19 is more contagious than these illnesses, spreads by human-to-human transmission via droplets, fecal or direct contact, and has an incubation period estimated at 1 to 14 days (usually 3 to 7 days).
-- The novel coronavirus 2019 epidemic and kidneys. Kidney International. 2020-03-07. | |
| we | present | distribution of incubation periods estimated for travellers with 2019-nCoV infection (count: 2) | |
| Here we present the distribution of incubation periods estimated for travellers from Wuhan with confirmed 2019-nCoV infection, using their reported travel histories and symptom onset dates.
-- The incubation period of 2019-nCoV infections among travellers from Wuhan, China. medrxiv. 2020-01-28. | |
| Here we present the distribution of incubation periods estimated for travellers from Wuhan with confirmed 2019-nCoV infection in the early outbreak phase, using their reported travel histories and symptom onset dates.
-- reference not found! | |
| COVID-19 patients | were becoming for | antibodies from 7-12 days (count: 2) | |
| COVID-19 patients were becoming reactive(positive) for specific antibodies from 7-12 days after the onset of morbidity.
| |
| Three COVID-19 patients were becoming reactive (positive) for specific anti-2019-nCoV antibodies from 7-12 days after the onset of morbidity, and the levels of anti-2019-nCoV IgM and IgG antibodies increased with the progression of the disease.
| |
| SARS-CoV-2 | been transmitted during | incubation period (count: 2) | |
| Moreover, there are evidences that SARS-CoV-2 appears to have been transmitted during the incubation period of patients in whom the illness was brief and nonspecific, whereas the detection of SARS-CoV-2 with a high viral load in the sputum of convalescent patients arouse concern about prolonged shedding of the virus after recovery [10] .
| |
| There are evidences that SARS-CoV-2 appears to have been transmitted during the incubation period of a patient, in whom the illness was brief and nonspecific [10] .
| |
| It | provides evidence on | mean incubation period of COVID-19 (count: 1) | |
| It provides additional evidence on the mean incubation period of COVID-19, which supports current practice of 14-day quarantine of persons with potential exposure but also suggests that longer monitoring periods might be needed for selected groups.
-- reference not found! | |
| 2019-nCoV coronavirus importation | detection of are | challenges to countries at risk of introduction from areas with active transmission (count: 1) | |
| Discussion Early detection of 2019-nCoV coronavirus importation and prevention of onward transmission are crucial challenges to all countries at risk of introduction from areas with active transmission in China.
-- Preparedness and vulnerability of African countries against introductions of 2019-nCoV. medrxiv. 2020-02-07. | |
| SARS-CoV-2 acid | remaining over | 14 days (count: 1) | |
| Notably, 5 (23.8%) patients in the LPV/r group experienced adverse events including 3 with diarrhea, 2 loss of appetite and one abnormal liver function, especially one serious adverse event reporting a 79-year-old man with diabetes and hypertension experienced severe diarrhea and progressed to critical condition ECMO with SARS-CoV-2 nucleic acid remaining positive over 14 days after treatment.
-- reference not found! | |
| SARS-CoV-2 acid | conversion of were | After 14 days 76.2 % (count: 1) | |
| After 14 days of treatment, the positive-to-negative conversion of SARS-CoV-2 nucleic acid were 76.2% (16/21), 87.5% (14/16) and 71.4% (5/7) respectively in the LPV/r group, the arbidol group and the control group, without significantly statistical difference among groups (P =0.681) (table 2).
-- reference not found! | |
| incubation period | were | analysed for features of patients with COVID-19 (count: 1) | |
| In addition, the median incubation period and disease course were analysed for epidemiological and clinical features of paediatric patients with COVID-19.
| |
| SARS-CoV-2 | Orf3b with | detectable protein homology (count: 1) | |
| However, they differ in their complement of 3' open reading frames: SARS-CoV-2 possesses an Orf3b and Orf10 with limited detectable protein homology to SARS-CoV 16 , and its Orf8 is intact while SARS-CoV encodes Orf8a and Orf8b (Fig.
-- reference not found! | |
| We | characterized | distribution of incubation periods for travellers infected with 2019-nCoV (count: 1) | |
| We characterized the distribution of incubation periods for Chinese travellers infected with 2019-nCoV in Wuhan, who were reported as cases between 20 and 28 January 2020.
-- The incubation period of 2019-nCoV infections among travellers from Wuhan, China. medrxiv. 2020-01-28. | |
| numerous COVID-19 case exportations | is in | recent days (count: 1) | |
| In summary, we suggest that the numerous COVID-19 case exportations from Italy in recent days suggest an epidemic that is larger than official case counts suggest, and which is approximately on a par .
-- Estimation of COVID-19 outbreak size in Italy based on international case exportations. medrxiv. 2020-03-06. | |
| active site | carries | six residues conserved among SARS-CoV-2 (count: 1) | |
| The active site, located in a shallow groove between the two b-sheets, carries six key residues conserved among SARS-CoV-2, SARS-CoV and MERS-CoV proteins: His235, His250, Lys290, Thr341, Tyr343, and Ser294 (Fig.
-- Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. biorxiv. 2020-03-03. | |
| COVID-19 | days of is | 5-10 days (count: 1) | |
| The incubation days of COVID-19 in Wuhan city is 5-10 days with a mean of 7 days (Fan et al.,
| |
| SARS-CoV-2 | be contagious during | incubation periods (count: 1) | |
| The incubation period of 2.0% (n=19 and 20 for male and female adults, respectively) of the total cases was 0-day, while some cases were transmitted by having contacts with Covid-19 patients who had not developed symptom onset yet, suggesting that SARS-CoV-2 might be contagious (i.e., is shedding virus) during incubation periods, and these patients could be more susceptible to this virus.
-- reference not found! | |
| pattern | was consistent with | data of SARS-CoV-2 viral shedding (count: 1) | |
| The observed pattern of secondary clinical attack rate over time was also consistent with the quantitative data of the SARS-CoV-2 viral shedding in upper respiratory specimens, which reported a high viral load around the time of symptom onset, followed by a gradual decrease in viral shedding to a low level after 10 days.
-- reference not found! | |
| C-reactive protein levels | were | risk factors for abnormalities in COVID-19 patients (count: 1) | |
| Multivariate analyses showed that C-reactive protein (CRP) levels, NCP severity, and underlying comorbidities were the risk factors for cardiac abnormalities in COVID-19 patients.
-- Acute Myocardial Injury of Patients with Coronavirus Disease 2019. medrxiv. 2020-03-08. | |
| = | consistent with | reports concerning incubation period of COVID-19 (count: 1) | |
| A. Parameter choices for best fits were a fixed basic reproduction number of R 0,free = 6.2 (note that this reproduction number corresponds to an unconstrained epidemic) and a fixed mean infection duration of T I = 8 d consistent with previous reports concerning the incubation period of COVID-19 [7, 13] .
| |
| SARS-CoV-2 RNA | was decreased to | anundetectable level (count: 1) | |
| Of note, SARS-CoV-2 RNA was decreased to anundetectable level in 3 patients on day 2, 3 patients on day 3 and 1 patients on day 6 after CP therapy.
-- reference not found! | |
| SARS-CoV-2 RNA | was detected at_time | 2-3 days (count: 1) | |
| SARS-CoV-2 RNA was detected every 2-3 days.
-- reference not found! | |
| COVID-19 cases | developed symptoms on | 3.3 days (count: 1) | |
| Our data also show that MTB infection is associated with more rapid development of symptoms ( Figure 1C-D) ; MTB coinfected COVID-19 cases developed symptoms on average 3.3 days earlier than their non-MTB-infected counterparts.
-- Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. medrxiv. 2020-03-16. | |
| latent/active TB | is | risk factor for SARS-CoV-2 infection (count: 1) | |
| First, the medical and wider community should be informed that latent/active TB is a risk factor for SARS-CoV-2 infection, and those at risk should be encouraged to pay special attention to preventive measures.
-- Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. medrxiv. 2020-03-16. | |
| Our assumption | is based on | estimates for incubation period of COVID-19 (count: 1) | |
| Our assumption of a 10-day lag is based on early estimates for the incubation period of COVID-19 (8) and prior estimates of the lag between symptom onset and detection for SARS (10) .
-- Risk for Transportation of 2019 Novel Coronavirus (COVID-19) from Wuhan to Cities in China. medrxiv. 2020-01-30. | |
| cases | were detectable Of | 225 non-COVID-19 cases (count: 1) | |
| Of 225 non-COVID-19 cases, 2 cases were detectable for influenza A RNA and 2 cases were detectable for influenza B RNA, respectively, 4 cases were detectable for adenovirus DNA, 17 cases were detectable for mycoplasma pneumonia DNA (Table 4 ).
| |
| antibodies | reactive to | 2019-nCoV (count: 1) | |
| In our study, we found that specific antibodies reactive to 2019-nCoV appeared from 7-12days after the onset of morbidity in all 3 patients.
| |
| SARS-CoV-2 infection | be ruled out | undetectable after 20 days (count: 1) | |
| This finding indicates that SARS-CoV-2 infection can be ruled out if antibody against SARS-CoV-2 is still undetectable after 20 days of symptoms onset, or after 23 days from exposure (20 days plus a median incubation of 3-day [9] ).
-- reference not found! | |
| SARS-CoV-2 travellers | have | Over weeks have reported within days (count: 1) | |
| Over the last few weeks, only a few SARS-CoV-2 infected travellers have been reported with symptoms within a few days after their arrival (15).
-- Interventions targeting air travellers early in the pandemic may delay local outbreaks of SARS-CoV-2. medrxiv. 2020-02-13. | |
| COVID-19 | period of is | about 5.2 days (count: 1) | |
| According to [6] , the incubation period of COVID-19 is about 5.2 days, thus ϕ can be set to be 1/5.2. ⟨
| |
| serum SARS-CoV-2 acid | is | detectable however (count: 1) | |
| Although the detection of throat-swab rather than serum SARS-CoV-2 viral load is widely used for the COVID-19 diagnosis, an undeniable fact is that serum SARS-CoV-2 nucleic acid (RNAaemia) is detectable in part of the patients, however, in what scenario it become detectable and whether the incidence of RNAaemia could be correlated with specific type of patients is not very clear.
| |
| 2019-nCoV | is infectious in | incubation period (count: 1) | |
| The relationship among the four groups is elucidated in Figure 1 , where β1 is the probability of S to E after I contacts S, γ1 is the probability of E to I, and γ2 is the probability of I to R. Since 2019-nCoV is also infectious in the incubation period, we introduced parameter β2 here to represent the probability of S to E after E contact S. We used the "susceptible exposedinfected -recovered" model [4] to describe the prevalent characteristics of 2019-nCoV in Wuhan .
-- When will the battle against novel coronavirus end in Wuhan: a SEIR modeling analysis. medrxiv. 2020-02-18. | |
| we | have inferred | distribution of incubation period of COVID-19 (count: 1) | |
| In the absence of complete and robust contact-tracing data, we have inferred the distribution of the incubation period of COVID-19 from the durations between departure from Wuhan and symptom onset for the confirmed cases.
| |
| period | should | should based on studies on incubation period of COVID-19 (count: 1) | |
| A 25-day follow-up period should be long enough based on the various studies on the incubation period of COVID-19. [
| |
| COVID-19 | for Group is | first quartile of 2 days (count: 1) | |
| In the study of Guan et al on behalf of China Medical Treatment Expert Group for COVID-19,the incubation period had a reported median of 4 days, the first quartile of 2 days and the third quartile of 7 days.4 By fitting a commonly used Weibull distribution to such quartiles, we can defined in Equation(2).
| |
| COVID-19 patients | developed kidney injury in | only 2 days (count: 1) | |
| It is noteworthy that most COVID-19 patients developed acute kidney injury in the early period of hospitalization, especially in only 2 days after admission in patients with elevated baseline Scr.
-- Kidney impairment is associated with in-hospital death of COVID-19 patients. medrxiv. 2020-02-20. | |
| Median anti-SARS-CoV-2 IgG | is in | patients with severe illness within 35 days after symptom onset (count: 1) | |
| Median anti-SARS-CoV-2 IgG and IgM levels in patients with severe or nonsevere illness within 35 days after symptom onset. (
| |
| decrease | was due to | refractive index of SARS-CoV-2 S1 RBD protein solution (count: 1) | |
| The initial decrease was due to a slightly lower refractive index of the SARS-CoV-2 S1 RBD protein solution compared to the PBS of the running buffer, which caused a negative bulk shift.
| |
| manufacturing | attractive strategy | responding to COVID-19 (count: 1) | |
| The subfractionation of existing heparin preparations against anticoagulant activities (with proven low-toxicity profiles, good bioavailability and industrial-scale manufacturing) for off-label pathologies, provides an attractive strategy for quickly and effectively responding to COVID-19 and for the development of next generation heparin-based therapeutics.
| |
| SARS-CoV-2-infected patients | produce | cross-reactive antibody responses 166 (count: 1) | |
| Nonetheless, some 165 SARS-CoV-2-infected patients were able to produce cross-reactive antibody responses 166 to SARS-CoV RBD.
-- Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. biorxiv. 2020-03-17. | |
| inhibitors | be active on | SARS-CoV-2 (count: 1) | |
| The high level of conservation of the IC and PBM within clade 2, including SARS-CoV-1 and SARS-CoV-2, strongly suggests that the available inhibitors for the E protein of SARS-CoV-1 should also be active on SARS-CoV-2.
| |
| COVID-19 patients | is in | only three six days (count: 1) | |
| We show here that hydroxychloroquine is efficient in clearing viral nasopharyngeal carriage of SARS-CoV-2 in COVID-19 patients in only three to six days, in most patients.
-- reference not found! | |
| mean SARS-CoV-2-positive duration | was | 9.71 days (count: 1) | |
| The mean SARS-CoV-2-positive duration from first positive test to conversion was 9.71 (95%CI, 8.21-11.22) days.
| |
| temperature | normalized SARS-CoV-2 RNA for | at least 3 days (count: 1) | |
| Patients were discharged from hospital if they met the criteria: temperature normalized for at least 3 days, apparent improvement in respiratory symptoms, absorption of lung inflammation, and negative SARS-CoV-2 genomic RNA tested for twice at 1 day interval.
| |
| duration | was | 9.24 days for COVID-19 patients (count: 1) | |
| This duration was 9.24 (7.10-11.37) days for COVID-19 patients without pneumonia (n=17) and 10.45 (8.10-12.81) days for those with pneumonia (n=11).
| |
| SARS-CoV-2 infection | incubation of was | 8.42 days (count: 1) | |
| As SARS-CoV-2 shares its receptor with SARS-CoV, 6 We revealed that the mean incubation of SARS-CoV-2 infection was 8.42 days.
| |
| SARS-CoV-2 | adding | mean incubation of 8.42 days (count: 1) | |
| SARS-CoV-2 might be present in patients for around 18 days by adding the mean incubation of 8.42 days.
| |
| COVID-19 incidence | could | Given incubation period could reflective (count: 1) | |
| Given the median incubation period of 4-6 days for COVID-19 [11] , the overall COVID-19 incidence in provinces with lags of 2-3 weeks, or approximately 2-3 times the median incubation period, could be reflective of the second-or third-generation transmissions.
| |
| We | relating | active COVID-19 cases (count: 1) | |
| We calculated pressures on EU healthcare systems by relating both country-specific accumulated COVID-19 deaths (intensityapproach) and active COVID-19 cases (magnitude-approach) to various estimates of hospital beds.
| |
| we | compared | number of active COVID-19 cases (count: 1) | |
| In a second measure, we compared the number of active COVID-19 cases, relative to the number of beds.
| |
| We | used | number of active COVID-19 cases (count: 1) | |
| We used the number of active COVID-19 cases and cumulative number of COVID-19 related deaths in Italy on March 11, 2020 as a benchmark.
| |
| tested | observed | course of 25 COVID-19 patients within 23 days (count: 1) | |
| tested in the real-time RT-PCR assay by using a SARS-We observed the clinical course of 25 COVID-19 patients within 23 days 2 5 5 of treatment.
| |
| It | know | incubation period of COVID-19 (count: 1) | |
| It is essential to know the accurate incubation period of COVID-19 for the sake of deciphering dynamics of its spread.
-- Estimate the incubation period of coronavirus 2019 (COVID-19). medrxiv. 2020-02-29. | |
| it | remains | unclear about its incubation period of COVID-19 (count: 1) | |
| However, it remains unclear about its exact incubation period of COVID-19, although WHO estimates it is between 2 to 14 days after exposure [8] .
-- Estimate the incubation period of coronavirus 2019 (COVID-19). medrxiv. 2020-02-29. | |
| we | estimate | incubation period of COVID-19 (count: 1) | |
| In this study, we aim to accurately estimate the incubation period of COVID-19 by taking advantage of datasets with a well-documented history of exposure.
-- Estimate the incubation period of coronavirus 2019 (COVID-19). medrxiv. 2020-02-29. | |
| COVID-19 incubation | percentile of is | 12.89 days (count: 1) | |
| That the estimated 97.5 th percentile of COVID-19 incubation is 12.89 days (95% CI: (11.00, 16.13)) may suggest a long isolation or quarantine time (e.g. 17 days) can be better than the widely accepted 14 days.
-- Estimate the incubation period of coronavirus 2019 (COVID-19). medrxiv. 2020-02-29. | |
| gender | affecting | incubation period of COVID-19 (count: 1) | |
| The results indicate that gender may not be a key factor affecting the incubation period of COVID-19.
-- Estimate the incubation period of coronavirus 2019 (COVID-19). medrxiv. 2020-02-29. | |
| We | estimate | incubation period of COVID-19 (count: 1) | |
| We estimate the incubation period of COVID-19 in this study and analyze its properties by employing statistical and machine learning techniques.
-- Estimate the incubation period of coronavirus 2019 (COVID-19). medrxiv. 2020-02-29. | |
| C-reactive protein | be predictive of | disease severity in COVID-19 patients (count: 1) | |
| Liu et al showed that C-reactive protein might be predictive of disease severity in COVID-19 infected patients.
| |
| patients | is in | incubation period of COVID-19 (count: 1) | |
| Meanwhile, patients in incubation period of COVID-19 underwent elective surgeries who were diagnosed after procedures made nosocomial infection quite a few on the early stage of the outbreak.
-- reference not found! | |
| incubation period | understanding | infectiousness of COVID-19 (count: 1) | |
| The incubation period also aids in understanding the relative infectiousness of COVID-19 and can be used to estimate the epidemic size [7] .
| |
| chest CT images | accompanied by | detectable SARS-CoV-2 RNA (count: 1) | |
| All patients had acute respiratory infection syndromes and/or abnormalities in chest CT images accompanied by detectable SARS-CoV-2 RNA in respiratory sample since illness onset for at least one time.
-- Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. medrxiv. 2020-03-03. | |
| SARS-CoV-2 | is in | patients with undetectable viral RNA (count: 1) | |
| Serological presence of antibodies against SARS-CoV-2 in patients with undetectable viral RNA at different time since onset of disease.
-- Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. medrxiv. 2020-03-03. | |
| women | leading to | incubation period of COVID-19 (count: 1) | |
| 22] that women have higher antiviral immunity than men, leading to a longer incubation period of COVID-19.
-- reference not found! | |
| we | analyzed | lymphocyte subsets in blood of COVID-19 patients to at least 16 days (count: 1) | |
| Next, we analyzed the kinetic changes of WBCs, neutrophils and monocytes as well as different lymphocyte subsets in the peripheral blood of COVID-19 patients from the disease onset to at least 16 days later.
| |
| infection | shed SARS-CoV-2 for | 5 days (count: 1) | |
| As reported by Pan et al [26] , 2 of 3 255 cases was asymptomatic infected, with the proportion of asymptomatic of 0.67.There was a research 256 showed that the asymptomatic infection would shed SARS-CoV-2 for 5 days [27] .
-- A mathematical model for estimating the age-specific transmissibility of a novel coronavirus. medrxiv. 2020-03-08. | |
| COVID-19 symptoms | appear after | 2-14 days (count: 1) | |
| COVID-19 symptoms are often (80%) mild [2] , may appear 2-14 days after exposure (mean incubation period 5-6 days) [2] , and include fever, cough and shortness of breath [3] .
-- reference not found! | |
| We | report | patterns of viral shedding in 94 COVID-19 patients (count: 1) | |
| We report temporal patterns of viral shedding in 94 laboratory-confirmed COVID-19 patients and modelled COVID-19 infectiousness profile from a separate sample of 77 infector-infectee transmission pairs.
-- reference not found! | |
| we | Assuming | incubation period from study of COVID-19 cases (count: 1) | |
| Assuming an incubation period with a mean of 5.2 days from a separate study of early COVID-19 cases, 2 we inferred that infectiousness started from 2.5 days before symptom onset and reached its peak at 0.6 days before symptom onset (Figure 1b) .
-- reference not found! | |
| we | data on | viral shedding before symptom onset for COVID-19 (count: 1) | |
| 12 Together this supports our findings that the infectiousness profile may more closely resemble that of influenza than of SARS (Figure 1a ), although we did not have data on viral shedding before symptom onset for COVID-19.
-- reference not found! | |
| we | assessed | viral shedding data from COVID-19 patients (count: 1) | |
| First, we assessed longitudinal viral shedding data from laboratory-confirmed COVID-19 patients starting from symptom onsets, where viral shedding during the first few days after illness onset can be compared with the inferred infectiousness.
-- reference not found! | |
| IgM | is | detectable in patients exposed to SARS-CoV-2 (count: 1) | |
| https://doi.org/10.1101/2020.03.17.20034454 doi: medRxiv preprint Further studies would be required to confirm their utility and better determine the time frame 136 when IgM and IgG is detectable in patients exposed to SARS-CoV-2.
-- reference not found! | |
| COVID-19 infection | can progress from | hospital admission in few as 2 days (count: 1) | |
| This is critical since COVID-19 infection can rapidly progress from hospital admission to ARDS in as few as 2 days, and COVID-19 infection can be fatal.
| |
| COVID-19 RT-LAMP products | were detectable on | gels (count: 1) | |
| The optimal time for detection of RT-LAMP products was 30 minutes, however COVID-19 RT-LAMP products were detectable by UV light excitation or banding patterns on gels in as little as 15 minutes.
| |
| three COVID-19 patients | had | reactive antibodies (count: 1) | |
| All three COVID-19 patients had reactive antibodies by both the IgG (6/10 serum samples) and IgA (7/10 serum samples) ELISAs (Figure 3) .
-- reference not found! | |
| 9 COVID-19 patients | were confirmed at | days (count: 1) | |
| All 9 COVID-19 patients were previously confirmed to seroconvert at days 6-15 post onset of disease using recombinant immunofluorescence test and PRNT.
-- reference not found! | |
| active case contact | is with | emerging transmission of SARS-CoV-2 (count: 1) | |
| These findings emphasize the need to strengthen public health interventions including active case contact tracing activities in countries with emerging transmission of SARS-CoV-2.
-- reference not found! | |
| C-Reactive Protein | reflect | changes in COVID-19 (count: 1) | |
| The routine blood test, procalcitonin (PCT), C-Reactive Protein (CRP) and Serum amyloid A (SAA) were used to reflect changes of inflammatory response in COVID-19.
| |
| it | fit within | active site of SARS-CoV-2 RdRp (count: 1) | |
| 16 In view of the fact that the active triphosphate form of TAF, Tenofovir diphosphate, is much smaller than natural nucleoside triphosphates, we expect that it can easily fit within the active site of SARS-CoV-2 RdRp.
-- reference not found! | |
| active surveillance | identified cases at | stage of COVID-19 (count: 1) | |
| This might be because active surveillance identified cases at an early stage of COVID-19.
-- reference not found! | |
| lockdown | are | effective in reduction with COVID-19 after about 11 days (count: 1) | |
| The daily statistics showed that lockdown are effective in reduction of incidence of confirmed cases with COVID-19 after about 11 days in china.
-- reference not found! | |
| works | have reported | incubation period of COVID-19 (count: 1) | |
| Based on patients' information, some works have reported the incubation period of COVID-19.
-- Epidemiological characteristics of 1212 COVID-19 patients in Henan, China. medrxiv. 2020-02-23. | |
| population | may carry COVID-19 for | days (count: 1) | |
| Those population may carry the COVID-19 for several days and might infect others who are closely contacting with, which makes the potentional risk.
| |
| COVID-19 | is disease with | incubation period (count: 1) | |
| COVID-19 is an emerging disease, with an incubation period of 1 to 14 (mostly 3 to 5) days.
-- reference not found! | |
| overactive inflammatory response | is in | patients with SARS-CoV-2 infection (count: 1) | |
| ACE2 is expressed in liver tissue and an overactive inflammatory response in patients with SARS-CoV-2 infection may cause increased ACE2 expression, and thus result in the observed liver tissue injury 5, 6 .
| |
| countries | reported 2019-nCoV cases in | days (count: 1) | |
| The first case outside China was witnessed on 13 January in Thailand [3] , and in the following days, several other countries also reported 2019-nCoV cases [4] .
-- Risk assessment of novel coronavirus COVID-19 outbreaks outside China. medrxiv. 2020-02-05. | |
| article | reported | transmission of SARS-CoV-2 infection from case in incubation period (count: 1) | |
| Until now, only one article reported transmission of SARS-CoV-2 infection from an asymptomatic case in the incubation period in Germany.
| |
| we | fit | curve of incubation period for COVID-19 (count: 1) | |
| As each individual's incubation period was a typically time-to-event, we used a Weibull distribution-based survival analysis model with the extension of Kaplan-Meier estimator to fit the curve of the incubation period for COVID-19
| |
| Our study | demonstrated | transmission of COVID-19 in three days (count: 1) | |
| Our study initially demonstrated asymptomatic transmission of COVID-19 in the incubation period, especially in the last three days of incubation period, by estimating the incubation period with the use of accurate exposure history of confirmed cases.
| |
| We | estimated | mean incubation period of COVID-19 infections (count: 1) | |
| We estimated the mean incubation period of COVID-19 infections to be 4.9 days, which was calculated based on a big sample size with valid data.
| |
| serial interval | was | 4.1 days for COVID-19 (count: 1) | |
| We observed the mean serial interval was 4.1 days for COVID-19, which is shorter than the 8.4-day and the 7.6-day mean serial interval reported for SARS and MERS, respectively.
| |
| study | provides | evidence of COVID-19 transmission during incubation period (count: 1) | |
| Therefore, this study provides a reliable incubation period and a strong evidence of the COVID-19 transmission during the incubation period.
| |
| COVID-19 cases | is in | incubation period (count: 1) | |
| In conclusion, the COVID-19 cases in the incubation period are potential infection sources, especially within three days prior to the symptom onset.
| |
| Chorology | confirmed | COVID-19 cases of incubation period (count: 1) | |
| Chorology of exposures and dates of symptom onset of 106 confirmed COVID-19 cases and distribution of the estimated incubation period. (
| |
| Factors | associated with | adoption phase COVID-19 epidemic past 14 days (count: 1) | |
| Factors associated with greater adoption of social-distancing interventions during the early phase of the COVID-19 epidemic in Hong Kong Presence of respiratory symptoms in the past 14 days
| |
| active actions | provide | support aiding in control of spread of COVID-19 (count: 1) | |
| China has taken active and effective actions to provide medical support for aiding in the control of the rapid spread of COVID-19.
-- Vicarious traumatization in the general public, members, and non-members of medical teams aiding in COVID-19 control. Brain, Behavior, and Immunity. 2020-03-10. | |
| 2019-nCoV | is capable during | its incubation period (count: 1) | |
| 2019-nCoV is capable of human-to-human transmission even during its asymptomatic incubation period (3-7 days [6] ).
-- Lockdown may partially halt the spread of 2019 novel coronavirus in Hubei province, China. medrxiv. 2020-02-13. | |
| 2019-nCoV strains | have | In days have separated (count: 1) | |
| Recently, a new type of pneumonia which is caused by 2019-nCoV has outbroken nationwide in China and the previous studies have shown that 2019-nCoV is like SARS-CoV. In the last few days, several 2019-nCoV strains have been successfully separated from patients and the results of sequencing data can be acquired on Sharing Avian Influenza Data and GenBank.
-- Predictions for the binding domain and potential new drug targets of 2019-nCoV. biorxiv. 2020-03-02. | |
| SARS-CoV-2 | turned after | 20 days (count: 1) | |
| Two children had fecal SARS-CoV-2 turned negative 20 days after throat swabs showing negative, while that of another child lagged behind for 8 days.
-- Prolonged presence of SARS-CoV-2 in feces of pediatric patients during the convalescent phase. medrxiv. 2020-03-13. | |
| SARS-CoV-2 RNA | remained | detectable in stools (count: 1) | |
| At this point, adult patients had negative results for nucleic acid testing in fecal specimens, whereas SARS-CoV-2 RNA remained detectable in stools from the two infected children.
-- Prolonged presence of SARS-CoV-2 in feces of pediatric patients during the convalescent phase. medrxiv. 2020-03-13. | |
| SARS-CoV-2 RNA | detectable in | feces (count: 1) | |
| 27 Xiao and colleagues demonstrated that about a quarter of COVID-19 patients had SARS-CoV-2 RNA detectable in feces after viral clearance in respiratory tract.
-- Prolonged presence of SARS-CoV-2 in feces of pediatric patients during the convalescent phase. medrxiv. 2020-03-13. | |
| SARS-CoV-2 RNA | was detected after | 8-20 days (count: 1) | |
| Notably, SARS-CoV-2 RNA was detected in the stool of these children 8-20 days after negative conversion of viral RNA in respiratory specimens.
-- Prolonged presence of SARS-CoV-2 in feces of pediatric patients during the convalescent phase. medrxiv. 2020-03-13. | |
| R0 | using incidence during | 23 days of COVID-19 Algeria (count: 1) | |
| In order to predict the cumulative incidence (cases number) of COVID-19 Algerian epidemic in the coming weeks we used the mathematical model (Alg-COVID-19) defined as: The approach implemented to estimate the basic reproduction numbers (R0) in this model is to calculate the average R0 using the real chronological incidence (case number) during the first 23 days of the COVID-19 Algeria epidemic between February 25 and March 19, 2020, so that, we used the equation (3) derived from the equation (1).
-- reference not found! | |
| future COVID-19 | confirmed cases with | weather observations in sequence of 15 days (count: 1) | |
| We used this best fitted model to predict future COVID-19 daily confirmed new cases with weather observations and forecasts in a sequence of 15 days for seven .
-- reference not found! | |
| days | is in | patients infected with COVID-19 (count: 1) | |
| However, current models of the population mortality impact of COVID-19 are based on agestratified death rates over days in patients infected with COVID-19 and have not incorporated clinical information from NHS health records regarding prevalence of underlying conditions, their differing background (pre-COVID-19) long term mortality risks, or the impact of differing levels of additional risk associated with COVID-19 (2) .
-- reference not found! | |
| we | estimated | incubation period of COVID-19 infection (count: 1) | |
| To identify accurately a timeframe for evaluating early shifts in SARS-CoV-2 transmission in China, we first estimated from case data the average incubation period of COVID-19 infection (i.e. the duration between time of infection and symptom onset (6, 7) ).
-- The effect of human mobility and control measures on the COVID-19 epidemic in China. medrxiv. 2020-03-06. | |
| active COVID-19 cases | is uniform across | state (count: 1) | |
| The daily active COVID-19 cases at the epidemic peak (hereafter, epidemic peak magnitude), is uniform across each state with a median value ≈ 7.59% of the state-wise population.
-- reference not found! | |
| children | be | in presence of active community transmission tested for COVID-19 (count: 1) | |
| 16 Based on the obtained data, we suggest that in the presence of active community transmission in a region, children presenting with a fever of unknown cause or with a fever in the presence of common cold or pneumonia symptoms should be tested for COVID-19 and influenza A and B.
| |
| COVID-19 | has force with | time of under 3 days (count: 1) | |
| We find that COVID-19 has a strong infectious force if left unchecked, with a doubling time of under 3 days.
-- reference not found! | |
| We | identified | set of SARS-reactive antibodies with cross-reactivity to SARS-CoV-2 RBD (count: 1) | |
| Here we report the crystal structure of the SARS-CoV-2 S receptor-binding-domain (RBD) at a the highest resolution to date, of 1.95 Å. We identified a set of SARS-reactive monoclonal antibodies with cross-reactivity to SARS-CoV-2 RBD and other betacoronavirus S glycoproteins.
-- A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein. biorxiv. 2020-03-17. | |
| COVID-19 | prevalence in | visitors staying only 3 days (count: 1) | |
| We find that for plausible parameters for COVID-19, prevalence in visitors staying only 3 days could be as little as half that of residents, but for longer stays of over a week the visitor prevalence should be 80% or more that of residents.
| |
| SARS-CoV-2 RNA | was detectable in | line (count: 1) | |
| SARS-CoV-2 was primarily detected in tissues of the respiratory tract, however SARS-CoV-2 RNA was also detectable in other tissues such as intestines, in line with a recent report (19).
-- reference not found! | |
| data | indicate | active replication of SARS-CoV-2 (count: 1) | |
| Together, these data indicate active replication of SARS-CoV-2 in the throat during the first 5 days after symptoms onset.
| |
| government | build | emergency hospital dedicated to COVID-19 patients in days (count: 1) | |
| To react to the exponential growth of infected patients requiring hospital-53 1 http://www.salute.gov.it/portale/nuovocoronavirus/ dettaglioContenutiNuovoCoronavirus.jsp isation, the Chinese government decided to build a large emergency hospital dedicated to COVID-19 patients in a few days.
-- reference not found! | |
| study | suggests With | With incubation period for SARS-CoV-2 (count: 1) | |
| With respect to the incubation period for SARS-CoV-2, a study in China [16] suggests that it may range from 2-14 days, with a median of 5.2 days.
-- reference not found! | |
| time | was | In study on 138 patients admitted with COVID-19 7 days (count: 1) | |
| In a retrospective Chinese study on 138 consecutive patients admitted with COVID-19, the median time from clinical onset to hospital admission was 7 days, 26% of patients were admitted to the ICU and 61% of them met clinical criteria for acute respiratory distress syndrome (ARDS) [5] .
| |
| we | estimate | incubation period for COVID-19 (count: 1) | |
| Based on 183 cases with a well defined period of exposure and symptom onset ( Figure S1 ), we estimate the median incubation period for COVID-19 to be 4.8 days (95% CI 4.2,5.4) [ Figure 2 , Table S2 ], and that 95% of those who develop symptoms will do so within 14.0 days (95% CI 12.2,15.9) of infection.
| |
| COVID-19 | period of is | 4.8 days (count: 1) | |
| We estimate the median incubation period of COVID-19 is 4.8 days (95%CI, 4.2, 5.4).
| |
| COVID-19 | interval of is | 5.4 days (count: 1) | |
| We estimated that the median serial interval of COVID-19 is 5.4 days (95% CI, 4.4 to 6.5).
| |
| COVID-19 | have | incubation period (count: 1) | |
| Different from SARS, however, the new 13 COVID-19 seems to have longer incubation period and thus is more contagious [11] .
| |
| 2019-nCoV ARD | period of was | 3.0 days (count: 1) | |
| The median incubation period of 2019-nCoV ARD was 3.0 days and it had a relatively lower fatality rate than SARS-CoV and MERS-CoV. Disease severity independently predicted the composite endpoint.
-- Clinical characteristics of 2019 novel coronavirus infection in China. medrxiv. 2020-02-09. | |
| 2019-nCoV | elicits spread with | incubation period (count: 1) | |
| In summary, 2019-nCoV elicits a rapid spread of outbreak with human-to-human transmission, with a median incubation period of 3 days and a relatively low fatality rate.
-- Clinical characteristics of 2019 novel coronavirus infection in China. medrxiv. 2020-02-09. | |
| lab-confirmed COVID-19 cases | detectable symptoms on | diagnosis (count: 1) | |
| The true fraction of subclinical COVID-19 cases remains unknown, but anecdotally, many lab-confirmed COVID-19 cases have not shown detectable symptoms on diagnosis (Hoehl et al.,
-- Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. eLife.; 9:e55570. 2020-02-24. | |
| 2019-nCoV | have | incubation period (count: 1) | |
| 8] , 2019-nCoV appears to have a shorter incubation period than severe acute respiratory syndrome (SARS), and a higher rate of asymptomatic infections [11] .
-- reference not found! | |
| we | find Due to | duration of incubation period of 2019-nCoV infection (count: 1) | |
| Due to the duration of the incubation period of 2019-nCoV infection, we find that exit or entry screening at airports for initial symptoms, via thermal scanners or similar, is unlikely to prevent passage of infected travellers into Each cell is a mean of 10,000 model simulations.
-- reference not found! | |
| COVID-19 surveillance | has in | has place since 10 January 2020 3 days after (count: 1) | |
| Specific COVID-19 surveillance has been in place in France since 10 January 2020, 3 days after the identification of the SARS-CoV-2 in China.
-- reference not found! | |
| probability | is negligible Given | estimations of SARS-CoV-2 incubation period (count: 1) | |
| Given the first estimations of the SARS-CoV-2 incubation period, the probability of secondary cases originating from those three cases is negligible.
-- reference not found! | |
| initial infections | is with | 2019-nCoV (count: 1) | |
| With a seemingly comparable chain of events as the origin of SARS-CoV, the initial infections with 2019-nCoV appears to be linked to contact with animals in wet markets.
-- 2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness. Journal of Infection in Developing Countries. 2020. | |
| market | to link is | time of travel of symptoms in two COVID-19 cases together incubation period of mean (count: 1) | |
| The missing link to the market, the time of travel and onset of symptoms in the two COVID-19 cases together with the incubation period of mean 6.4 days (range: 5.6-7.7)[16] and the time of closest genome neighbours obtained from sequences in Wuhan, suggest that transmission within Wuhan beyond the Huanan Seafood Market is likely to have occurred in the first week of January or earlier.
| |
| strong interaction | is with | active site of SARS-CoV-2 main protease (count: 1) | |
| Our results showed that several HIV inhibitors such as lopinavir, ritonavir, and saquinavir produce strong interaction with the active site of SARS-CoV-2 main protease.
-- reference not found! | |
| SARS-CoV-2 protease | has | active site (count: 1) | |
| SARS-CoV-2 protease has an active site with a surface accessible to solvent of 356Å and SARS-CoV only 256 Å (Figure 3 ).
-- reference not found! | |
| protease inhibitors | interact with | active site of SARS-CoV-2 protease (count: 1) | |
| In silico data demonstrated that the different protease inhibitors, used against HIV-1, could interact with the active site of SARS-CoV-2 protease producing an interaction with a binding energy lower than -6.9 Kcal/mol.
-- reference not found! | |
| COVID-19 patient | had | cough 2 days (count: 1) | |
| On 6 February 2020, a recovered COVID-19 patient in Changde (Hunan province, China) had a fever and cough 2 days after discharge, and chest CT showed worsened status [12] .
-- reference not found! | |
| patient | is with | confirmed 2019-nCoV infection within past 14 days (count: 1) | |
| 4) Have you come into contact with a patient with confirmed 2019-nCoV infection within the past 14 days? (
-- Transmission routes of 2019-nCoV and controls in dental practice. International Journal of Oral Science. 2020. | |
| studies | have assumed incubation periods In | absence of data on 2019-nCoV incubation period (count: 1) | |
| In absence of data on the 2019-nCoV incubation period, these studies have assumed incubation periods of SARS or MERS coronaviruses.
-- reference not found! | |
| mean incubation periods | are variable between | studies including values shorter than those presented for 2019-nCoV (count: 1) | |
| The estimated mean incubation periods for SARS are more variable between studies, including values shorter and longer than those presented here for 2019-nCoV. These findings imply that the findings of previous studies that have assumed incubation period distributions similar to MERS or SARS will not have to be adapted because of a shorter or longer incubation period.
-- reference not found! | |
| We | characterised | distribution of incubation periods for travellers infected with 2019-nCoV (count: 1) | |
| We characterised the distribution of incubation periods for travellers from Wuhan infected with 2019-nCoV in Wuhan who were reported as cases between 20 and 28 January 2020.
-- reference not found! | |
| COVID-19 cases | is in | 14 days (count: 1) | |
| A laboratoryconfirmed case of COVID-19 was defined a patient with positive real-time RT-PCR to SARS-CoV-2, while a suspected case was defined as a patient with history of travelling to Wuhan City or in contact with COVID-19 cases in the 14 days before onset of symptoms and with clinical manifestation of fever, respiratory illness, pneumonia on computed tomography (CT) scan, and/or reduced white blood cells count, but no RT-PCR results.
-- reference not found! | |
| interest | was | 10-14 days earlier than incidence peak of COVID-19 (count: 1) | |
| We also found that the peak interest for these keywords in Internet search engines and social media data was 10-14 days earlier than the incidence peak of COVID-19 published by the NHC.
-- reference not found! | |
| we | have | wait for at least 14 days after anti-COVID-19 epidemic (count: 1) | |
| In other words, we have to wait for at least 14 days after the massive anti-COVID-19 epidemic without using information derived from F ′ ′ (x).
-- First two months of the 2019 Coronavirus Disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model. Global Health Research and Policy. 2020. | |
| efforts | detecting | detectable COVID-19 (count: 1) | |
| 2 and 3 (Phase 4 and 5), three pieces of information can be derived: (1) The epidemic was highly sensitive to external interventions, supporting the nonlinear and chaotic characters revealed by the long latent period in the first three phases; (2) the massive national efforts were highly effective in detecting the detectable COVID-19; (3) signal for the COVID-19 in China to decline appeared on January 21 in 2020, 14 days before the start of eventual declines on February 4, as indicated by F ′ ′ (x) and F ′ (x) in Fig.
-- First two months of the 2019 Coronavirus Disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model. Global Health Research and Policy. 2020. | |
| COVID-19 epidemic | was responsive Despite | delay of 43 days (count: 1) | |
| Despite a delay of 43 days from the first confirmed cases on December 8, 2019 to January 20, 2020, the COVID-19 epidemic was highly responsive to massive interventions, supporting the effectiveness of these interventions.
-- First two months of the 2019 Coronavirus Disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model. Global Health Research and Policy. 2020. | |
| 2019-nCoV virus infection | is in | persons with travel with compatible incubation period (count: 1) | |
| Clinicians should consider the possibility of 2019-nCoV virus infection in persons with travel or exposure history with compatible incubation period and presenting symptoms.
-- Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP). J Chin Med Assoc. 2020. | |
| COVID-19 | is with | mean of 7.5 days (count: 1) | |
| Therefore, we assumed the serial interval of COVID-19 on the ship was equal to that of COVID-19 in Wuhan, China, with a mean of 7.5 days and a standard deviation of 3.4 days .
-- reference not found! | |
| C-reactive protein | are | factors associated with prognosis of COVID-19 infection (count: 1) | |
| The present study suggests that elevated C-reactive protein, and decreased albumin are factors associated with poor prognosis of COVID-19 infection.
-- Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020. | |
| Montelukast | was fitted in | active pocket of SARS-CoV-2 3CLpro (count: 1) | |
| A) Montelukast was fitted well in the active pocket of SARS-CoV-2 3CLpro, 3CLpro was shown as electrostatic surface model. (
-- reference not found! | |
| COVID-19 | period of be | 10 days (count: 1) | |
| where the infectious period equals to one over the recovery rate ( ), In the homogeneous model, the infectious period, i, of COVID-19 was set to be 10 days based on previous findings.
-- COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures. Journal of Travel Medicine. 2020. | |
| SARS-CoV-2 | be transmitted during | incubation period (count: 1) | |
| A recent study of 138 hospitalized COVID-19 patients shows that SARS-CoV-2 can be transmitted from person to person through droplets and hand contact during an incubation period as well as on acute attack [2] .
-- Fear can be more harmful than the severe acute respiratory syndrome coronavirus 2 in controlling the corona virus disease 2019 epidemic. World J Clin Cases. 2020 Feb 26. | |
| measures | entry of | active COVID-19 cases (count: 1) | |
| Although these measures may prevent the entry of active COVID-19 cases, history taught us that this system is not fully effective in preventing virus introduction into a country.
-- COVID-19 in the Shadows of MERS-CoV in the Kingdom of Saudi Arabia. Journal of Epidemiology and Global Health. 2020. | |
| it | be | 3-6 days for 2019-nCoV (count: 1) | |
| Overall, infection caused by the 2019-nCoV shares many clinical similarities with infection caused by SARS-CoV. A typical human coronavirus has an incubation period of 2-4 days; it is estimated to be 3-6 days for the 2019-nCoV, and 4-6 days for SARS-CoV. 15, 16, 29, 30 Infection with 2019-nCoV, similar to SARS-CoV, presents with non-specific symptoms such as malaise, fever, and dry cough at the prodromal phase.
-- The Novel Coronavirus: A Bird's Eye View. Int J Occup Environ Med. 2020. | |
| SARS-CoV-2 | been transmitted in | stage of incubation period (count: 1) | |
| The present report suggests that the SARS-CoV-2 may have been transmitted in theterminal stage of incubation period.
-- Transmission of COVID-19 in the terminal stage of incubation period: a familial cluster. International Journal of Infectious Diseases. 2020-03-16. | |
| SARS-CoV-2 | is detected within | 1-2 days (count: 1) | |
| Subsequent detailed clinical investigations demonstrated that SARS-CoV-2 is detected within 1-2 days after patient symptoms, peaking 4-6 days later and clearing within 18 days [4] .
-- SARS Coronavirus Redux. Trends in Immunology. 2020-03-12. | |
| serial interval | is | for COVID-19 estimated at 4 · 4-7 · 5 days (count: 1) | |
| 3 By contrast, for COVID-19, the serial interval is estimated at 4·4-7·5 days, which is more similar to SARS.
-- How will country-based mitigation measures influence the course of the COVID-19 epidemic?. The Lancet. 2020-03-09. | |
| COVID-19 | had | time of about 4-5 days (count: 1) | |
| COVID-19 had a doubling time in China of about 4-5 days in the early phases.
-- How will country-based mitigation measures influence the course of the COVID-19 epidemic?. The Lancet. 2020-03-09. | |
| SARS-CoV-2 | was | found days ago (count: 1) | |
| Since SARS-CoV-2 was found a few days ago to utilise the same cell surface receptor ACE2 (expressed in lung, heart, kidney and intestine) as SARS-CoV-1 [85, 86] (Table 1) , it may be hypothesised that chloroquine also interferes with ACE2 receptor glycosylation thus preventing SARS-CoV-2 binding to target cells.
-- New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. International Journal of Antimicrobial Agents. 2020-03-12. | |
| patient | had | SARS-CoV-2 RNA detected for 25 days (count: 1) | |
| SARS-CoV-2 RNA could be detected for 20 days or longer in a third of patients who survived in our cohort, and one patient had SARS-CoV-2 RNA detected for 25 days.
-- reference not found! | |
| stable STEMI patient | is with | active COVID-19 (count: 1) | |
| Fibrinolysis can be considered an option for the relatively stable STEMI patient with active COVID-19.
-- reference not found! | |
| patients | is with | active COVID-19 primary PCI is (count: 1) | |
| In patients with active COVID-19 in whom primary PCI is to be performed, appropriate personal protective equipment (PPE) should be worn including gown, gloves, goggles (or shields), and a N95 mask, especially given the limited ability to take a history from the patient as well as the potential for clinical deterioration in STEMI cases.
-- reference not found! | |
| COVID-19 infection | period of is | approximately 5.2 days (count: 1) | |
| The incubation period of COVID-19 infection is approximately 5.2 days.
-- The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020-02-26. | |
| COVID-19 importation | detection of are | challenges to countries at risk from areas with active transmission (count: 1) | |
| Early detection of COVID-19 importation and prevention of onward transmission are crucial challenges to all countries at risk of importation from areas with active transmission in China.
-- Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. The Lancet. 2020-03-20. | |
| COVID-19 particles | survive | days (count: 1) | |
| 4 Emerging research also suggests that COVID-19 viral particles remain viable in aerosol for several hours and can survive several days on multiple surfaces.
-- reference not found! | |
| coronaviruses | have | incubation periods COVID-19 appearing (count: 1) | |
| In humans, these coronaviruses have short incubation periods, ranging from days for SARS-CoV and weeks for MERS-CoV, with the COVID-19 appearing to fall in between the two.
-- Guide to Understanding the 2019 Novel Coronavirus. Mayo Clinic Proceedings. 2020-02-28. | |
| COVID-19 | is showing deterioration after | 7-9 days (count: 1) | |
| COVID-19 is showing respiratory deterioration 7-9 days after onset, which is double the 3-5 days period documented in influenza pandemic, suggesting that it cannot be related to the viral load.
-- Coronavirus Disease 2019 (COVID-19): A critical care perspective beyond China. Anaesthesia Critical Care & Pain Medicine. 2020-03-03. | |
| SARS-CoV-2 | has | From days has topic (count: 1) | |
| From the first days of 2020, SARS-CoV-2 has been the main topic discussed all over the world.
-- reference not found! | |
| suspected positive SARS-CoV-2 infected patients | is in | last 14 days (count: 1) | |
| At the department entrance, patients were asked to fill in a special medical history form; the form required to declare respiratory symptoms and contacts with people with suspected or confirmed positive SARS-CoV-2 infected patients in the last 14 days.
-- reference not found! | |
| Correspondence | were | tested for SARS-CoV-2 Q3 acid at 14 days (count: 1) | |
| Correspondence to S. Liu (13543456446@139.com) patients were tested for SARS-CoV-2 Q3 nucleic acid at admission and at 14 days, remaining negative.
-- reference not found! | |
| SARS-CoV-2 acid test results | were negative After | 8 days (count: 1) | |
| After 8 days of treatment, the SARS-CoV-2 nucleic acid test results were negative in throat swab samples twice, cough had improved, and laboratory tests results and computed tomographic chest images had improved (Fig 1) .
-- reference not found! | |
| IDX-184 | can | can used as seed for compounds specific against SARS-CoV-2 RdRp active site (count: 1) | |
| Additionally, IDX-184 can be used as a seed for new compounds specific against SARS-CoV-2 RdRp active site.
-- reference not found! | |
| 7 Use | is in | patients with COVID-19 over 7-14 days (count: 1) | |
| 7 Use of this agent in patients with COVID-19 over 7-14 days, for example, suggests sideeffects would be trivial.
-- COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases. 2020-02-27. | |
| SARS-CoV-2 | is propagated cough with | incubation period (count: 1) | |
| The SARS-CoV-2 is primarily propagated through respiratory droplets and close contact, with the incubation period usually between 1 and 14 days and the typical symptoms after onset of fever, dry cough, fatigue and gradual appearance of dyspnea.
-- Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. Journal of Infection. 2020-02-25. | |
| SARS-CoV-2 | pneumonia for | six days (count: 1) | |
| Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2, Journal of Infection, https://doi.org/10.1016/j.jinf.2020.Common novel coronavirus pneumonia in a 37-year-old man with fever for six days and cough for two days before admission.
-- Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. Journal of Infection. 2020-02-25. | |
| SARS-CoV-2 | was | detectable until death (count: 1) | |
| Median duration of viral shedding was 20·0 days (IQR 17·0-24·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors.
| |
| detectable SARS-CoV-2 RNA | persisted for | median (count: 1) | |
| In the current study, we found that the detectable SARS-CoV-2 RNA persisted for a median of 20 days in survivors and that it was sustained until death in nonsurvivors.
| |
| COVID-19 | spread in | just 30 days (count: 1) | |
| In summary, COVID-19 is high in prevalence and population is generally susceptible to such virus, and COVID-19 rapidly spread from a single Wuhan city to the entire country in just 30 days.
-- reference not found! | |
| SARS-CoV-2 patients | is in | incubation period (count: 1) | |
| However, there is still a debate about whether SARS-CoV-2 patients in the incubation period are infectious, which needs further study.
-- reference not found! | |
| COVID-19 | is shorter From | incubation period (count: 1) | |
| From the median incubation period, COVID-19 is shorter than SARS and MERS.
-- reference not found! | |
| COVID-19 | infection with | incubation period (count: 1) | |
| COVID-19 produces an acute viral infection in humans with median incubation period was 3.0 days [15] , which is similar to the SRAS with an incubation period ranging from 2-10 days [30] .
-- reference not found! | |
| time | was | only 9 days among patients with COVID-19 infection (count: 1) | |
| Most patients had some degree of dyspnoea at presentation, because the time from onset of symptoms to the development of acute respiratory distress syndrome (ARDS) was only 9 days among the initial patients with COVID-19 infection [1] .
-- reference not found! | |
| SARS-CoV-2 acid | be detectable in | tract specimens (count: 1) | |
| We also found that SARS-CoV-2 nucleic acid might still be detectable in the lower respiratory tract specimens although negative results of throat swab detection.
-- Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19. Travel Medicine and Infectious Disease. 2020-03-08. | |
| study | viral shedding in | feces of eight patients with SARS-CoV-2 infection (count: 1) | |
| Discussion: This study found viral shedding in the feces of eight patients with SARS-CoV-2 infection, six of whom were children.
-- reference not found! | |
| transmission | occurring during | incubation period of COVID-19 (count: 1) | |
| However, there is an increasing body of evidence to suggest that human-to-human transmission may be occurring during the asymptomatic incubation period of COVID-19, which has been estimated to be between 2 and 10 days [20] [21] [22] .
-- World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery. 2020-04-30. | |
| COVID-19 | have | mean incubation period (count: 1) | |
| To date, COVID-19 has been shown to have a mean incubation period of 5.2 days and a median duration from the onset of symptoms to death of 14 days [22, 39] , which is comparable to that of MERS [40] .
-- World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery. 2020-04-30. | |
| COVID-19 | has spread within | 60 days (count: 1) | |
| COVID-19 has spread globally within 60 days with focus areas in Asia, Europe and the Middle East [2] .
-- reference not found! | |
| finding | reflected | increased until three days before increased of COVID-19 cases (count: 1) | |
| This finding reflected the increased of googling activities in one until three days before the increased of COVID-19 cases.
-- Applications of google search trends for risk communication in infectious disease management: A case study of COVID-19 outbreak in Taiwan. International Journal of Infectious Diseases. 2020-03-12. | |
| COVID-19 | because of | incubation period (count: 1) | |
| Finally, a recent report (5) suggests that 46% of cases would be missed by airport-based screening because of COVID-19's incubation period, the spectrum of symptoms, and the time during the incubation period in which persons may fly.
-- reference not found! | |
| COVID-19 patients | be infectious during | incubation period (count: 1) | |
| This report suggested that, in contrast to SARS, COVID-19 patients might be infectious during an asymptomatic incubation period.
-- Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfusion Medicine Reviews. 2020-02-21. | |
| active smoking | be associated with | risk progressing in COVID-19 (count: 1) | |
| Despite a trend towards higher risk was appreciable, no significant association could neither be found between active smoking and severity of COVID-19 when data of individual studies were pooled (OR, In conclusion, the results of this preliminary meta-analysis based on Chinese patients suggest that active smoking does not apparently seem to be signicantly associated with enhanced risk of progressing towards severe disease in COVID-19.
-- Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). European Journal of Internal Medicine. 2020-03-16. | |
| patient 's family members | have | have diagnosed with 2019-nCoV infection within 14 days (count: 1) | |
| being at high risk of 2019-nCoV infection because the patient's family members or caregivers have been diagnosed with 2019-nCoV infection, had close contact with someone with probable or confirmed 2019-nCoV, had close contact with someone with pneumonia of unknown cause, are living in or travelling to epidemic areas, or have been in animal markets or close contact with wild animals, within 14 days before the onset of illness.
-- A contingency plan for the management of the 2019 novel coronavirus outbreak in neonatal intensive care units. The Lancet Child & Adolescent Health. 2020-04-30. | |
| period | appeared | short consistent with reports of incubation period of SARS-CoV-2 6 (count: 1) | |
| Based on this assumption, the period from exposure to disease onset appeared short, at approximately 48 hours, consistent with recent reports of the incubation period of SARS-CoV-2 6 .
-- Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission. Journal of Infection. 2020-02-28. | |
| she | was | With three 41 results of RT-PCR tests for SARS-CoV-2 discharged after 24 days (count: 1) | |
| With three 41 consecutive negative results of real-time RT-PCR tests for SARS-CoV-2 in 42 nasopharyngeal swab, she was discharged after 24 days of hospitalization.
-- A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic. Journal of Microbiology, Immunology and Infection. 2020-03-10. | |
| SARS-CoV-2 | detected in | their swabs 44 sampled after 14 days ' quarantine (count: 1) | |
| None of 43 four members in the family had SARS-CoV-2 detected in their nasopharyngeal swabs 44 sampled after 14 days' quarantine.
-- A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic. Journal of Microbiology, Immunology and Infection. 2020-03-10. | |
| We | reported | median incubation period of SARS-CoV-2 (count: 1) | |
| We reported the median (IQR) incubation period of SARS-CoV-2.
-- Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. The Lancet. 2020-03-17. | |
| we | provide | estimates of incubation period of COVID-19 (count: 1) | |
| In this article, we provide estimates of the incubation period of COVID-19 and the number of symptomatic infections missed under different active monitoring scenarios.
-- reference not found! | |
| persons | are | exposed to SARS-CoV-2 before active monitoring program (count: 1) | |
| This model conservatively assumes that persons are exposed to SARS-CoV-2 immediately before the active monitoring program and assumes perfect ascertainment of symptomatic cases that develop under active monitoring.
-- reference not found! | |
| COVID-19 | period of be | 5.1 days (count: 1) | |
| Fitting the log-normal model to all cases, we estimated the median incubation period of COVID-19 to be 5.1 days (CI, 4.5 to 5.8 days) (Figure 2) .
-- reference not found! | |
| We | estimated | incubation period of COVID-19 (count: 1) | |
| We estimated the median incubation period of COVID-19 to be 5.1 days and expect that nearly all infected persons who have symptoms will do so within 12 days of infection.
-- reference not found! | |
| work | provides | evidence for incubation period for COVID-19 (count: 1) | |
| This work provides additional evidence for a median incubation period for COVID-19 of approximately 5 days, similar to SARS.
-- reference not found! | |
| He | was | discharged after 8 days following two nose negative for SARS-CoV-2 (count: 1) | |
| He was discharged after 8 days, following two sequential nose and throat swabs negative for SARS-CoV-2 by PCR.
-- reference not found! | |